Intellectus Partners LLC Has $1.06 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Intellectus Partners LLC grew its stake in Novo Nordisk A/S (NYSE:NVO) by 9.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,884 shares of the company’s stock after acquiring an additional 749 shares during the period. Intellectus Partners LLC’s holdings in Novo Nordisk A/S were worth $1,058,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of NVO. 1620 Investment Advisors Inc. bought a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at about $25,000. Gilliland Jeter Wealth Management LLC boosted its stake in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after acquiring an additional 120 shares during the last quarter. Strategic Investment Solutions Inc. IL acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth $25,000. Orion Capital Management LLC bought a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $26,000. Finally, Halpern Financial Inc. lifted its stake in shares of Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock valued at $30,000 after purchasing an additional 113 shares during the period. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NVO. BMO Capital Markets cut their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NVO stock opened at $105.35 on Friday. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The company’s fifty day simple moving average is $119.68 and its 200-day simple moving average is $129.92. The firm has a market cap of $472.76 billion, a PE ratio of 34.09, a P/E/G ratio of 1.31 and a beta of 0.42. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.